There’s A New Coronavirus Vaccine In Trial, And It’s Showing Promise
. Our hope for a return to social and economic normalcy hinges on the production of a safe, effective vaccine.
Moderna, Inc., of Cambridge, Mass., has emerged as one of the frontrunners in this endeavor. In collaboration with the National Institute of Allergy and Infectious Diseases, the company began human trials on a group of about 600 test subjects on May 7. The primary goal for that first phase was to determine if the vaccine was safe. Initial results,, suggest that not only does the vaccine appear to be safe, it also seems to elicit the kind of immune response necessary to prevent disease.
For the first part of the trial, 45 volunteers were divided into three groups, with three different dosage levels administered to each group. All groups receive a booster shot one month after their initial dose. Moderna reported that trial participants have had only mild side effects such as redness at the injection site, headache, fever, and flu-like symptoms, none of which lasted for more than a day.
Moderna has been given the go ahead by the Food and Drug Administration to begin a second phase of testing which will involve an additional 600 people,
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Asian stocks rise after Moderna's coronavirus vaccine delivers early positive results | Markets InsiderAsian stocks rose on Tuesday after Moderna reported promising results from the first human trials of its coronavirus vaccine. US futures slid af...
Read more »
Early Results from Coronavirus Vaccine Trial Show Promising Immune ResponseHospital’s First Coronavirus Patient Discharged After Two Months\n
Read more »
Asia Pacific stocks set to open mixed as investors await release of China's benchmark lending rateInvestors will also watch for market reaction to a STAT News report released overnight that raised concerns about the trial results for a potential coronavirus vaccine from Moderna.
Read more »
Treasury yields fall as investors monitor coronavirus vaccine and recovery hopesU.S. government debt prices were higher Tuesday morning, coming off a surge during the previous session following news of promising early testing of an experimental coronavirus vaccine.
Read more »
Promising Early Stage Vaccine Trial Sends Stocks SoaringEight healthy patients who received the vaccine developed antibodies at levels similar to those who’ve recovered from COVID-19.
Read more »
Coronavirus vaccine czar to divest some holdings amid conflict concernsPresident Trump's newly appointed vaccine czar, Moncef Slaoui, plans to divest his equity holdings in a company leading the coronavirus vaccine development effort, the Department of Health and Human Services told ABC News.
Read more »